These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37190755)

  • 1. Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer.
    Bhatia N; Khator R; Kulkarni S; Singh Y; Kumar P; Thareja S
    Curr Med Chem; 2023; 30(32):3668-3701. PubMed ID: 37190755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
    Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
    Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
    Weber L
    Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present).
    Rusiecki R; Witkowski J; Jaszczewska-Adamczak J
    Recent Pat Anticancer Drug Discov; 2019; 14(4):324-369. PubMed ID: 31642413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
    Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
    Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
    Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
    Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update.
    Millard M; Pathania D; Grande F; Xu S; Neamati N
    Curr Pharm Des; 2011; 17(6):536-59. PubMed ID: 21391905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.
    Lu Y; Nikolovska-Coleska Z; Fang X; Gao W; Shangary S; Qiu S; Qin D; Wang S
    J Med Chem; 2006 Jun; 49(13):3759-62. PubMed ID: 16789731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 as a potential target for treatment of cancer: A perspective on recent advancements in small molecules with structural insights and SAR studies.
    Chahat ; Bhatia R; Kumar B
    Eur J Med Chem; 2023 Feb; 247():115020. PubMed ID: 36543034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction.
    Beloglazkina A; Zyk N; Majouga A; Beloglazkina E
    Molecules; 2020 Mar; 25(5):. PubMed ID: 32156064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLICation: engineering approved drugs as potential p53-MDM2 interaction inhibitors for cancer therapy.
    Patil SP
    Med Hypotheses; 2013 Dec; 81(6):1104-7. PubMed ID: 24210632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
    Chène P
    Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53-Mdm2 inhibitors: patent review (2009 - 2010).
    Kamal A; Mohammed AA; Shaik TB
    Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
    Haronikova L; Bonczek O; Zatloukalova P; Kokas-Zavadil F; Kucerikova M; Coates PJ; Fahraeus R; Vojtesek B
    Cell Mol Biol Lett; 2021 Dec; 26(1):53. PubMed ID: 34911439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
    Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
    Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
    Shangary S; Wang S
    Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.
    Zhu H; Gao H; Ji Y; Zhou Q; Du Z; Tian L; Jiang Y; Yao K; Zhou Z
    J Hematol Oncol; 2022 Jul; 15(1):91. PubMed ID: 35831864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.